ERX1595165 E-MTAB-4917:MEM001_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242632 SAMEA4071522 MEM001_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::NRASQ61K/ genotype Experimental Factor: melanoma disease ERX1595166 E-MTAB-4917:MEM002_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242633 SAMEA4071523 MEM002_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::NRASQ61K/ genotype Experimental Factor: melanoma disease ERX1595167 E-MTAB-4917:MEM003_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242634 SAMEA4071524 MEM003_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::NRASQ61K/ genotype Experimental Factor: normal disease ERX1595168 E-MTAB-4917:MEM004_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242635 SAMEA4071525 MEM004_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::NRASQ61K/ genotype Experimental Factor: normal disease ERX1595169 E-MTAB-4917:MEM005_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242636 SAMEA4071526 MEM005_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::Cre;Tyr::NRASQ61K/; Trp53l/l genotype Experimental Factor: melanoma disease ERX1595170 E-MTAB-4917:MEM006_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242637 SAMEA4071527 MEM006_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::Cre;Tyr::NRASQ61K/; Trp53l/l genotype Experimental Factor: normal disease ERX1595171 E-MTAB-4917:MEM007_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242638 SAMEA4071528 MEM007_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: melanoma disease ERX1595172 E-MTAB-4917:MEM008_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242639 SAMEA4071529 MEM008_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: normal disease ERX1595173 E-MTAB-4917:MEM009_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242640 SAMEA4071530 MEM009_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::Cre;Tyr::NRASQ61K/; Trp53l/l genotype Experimental Factor: melanoma disease ERX1595174 E-MTAB-4917:MEM010_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242641 SAMEA4071531 MEM010_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::Cre;Tyr::NRASQ61K/; Trp53l/l genotype Experimental Factor: normal disease ERX1595175 E-MTAB-4917:MEM011_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242642 SAMEA4071532 MEM011_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: melanoma disease ERX1595176 E-MTAB-4917:MEM011_N1_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242643 SAMEA4071533 MEM011_N1_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: normal disease ERX1595177 E-MTAB-4917:MEM012_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242644 SAMEA4071534 MEM012_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: melanoma disease ERX1595178 E-MTAB-4917:MEM012_N1_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242645 SAMEA4071535 MEM012_N1_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: normal disease ERX1595179 E-MTAB-4917:MEM013_N1_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242646 SAMEA4071536 MEM013_N1_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: normal disease ERX1595180 E-MTAB-4917:MEM015_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242647 SAMEA4071537 MEM015_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: melanoma disease ERX1595181 E-MTAB-4917:MEM016_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242648 SAMEA4071538 MEM016_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;LSL-BRafV600E/+;Ink4a-/- genotype Experimental Factor: melanoma disease ERX1595182 E-MTAB-4917:MEM017_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242649 SAMEA4071539 MEM017_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;BRafCA/+ genotype Experimental Factor: melanoma disease ERX1595183 E-MTAB-4917:MEM018_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242650 SAMEA4071540 MEM018_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;BRafCA/+ genotype Experimental Factor: melanoma disease ERX1595184 E-MTAB-4917:MEM019_p ERP016415 Integrative and comparative genomics identifies the tyrosine kinase FES as a key melanoma tumor supppressor: WES ERS1242651 SAMEA4071541 MEM019_p WXS GENOMIC Hybrid Selection The transgenic Tyr::CreERT2, BRafCA/+, LSL-BRafV600E/+, Ink4a-/-, Ptenfl/fl, Tyr::NRasQ61K/°, Trp53-/- , Trp53fl/fl, R26RLSL-eYFP mouse lines were described previously (Bosenberg M et al., 2006; Dankort D et al., 2007; Mercer et al., 2005, Krimpenfort P et al., 2001; Lesche R et al., 2002; Ackermann J et al., 2005; Jacks T et al., 1994; Jonkers, J. et al., 2001; Srinivas S et al., 2001) and were provided by Sheri Holmen and Lionel Larue. The characterization of Fes-/- mice has been reported previously and was genotyped and assayed for recombination using PCR (Zirngibl RA et al., 2002). The resulting cohorts of mice were on mixed genetic backgrounds consisting of C57BL/6J, 129 and FVB. The amplified DNA libraries were hybridized to a complete set of biotinylated long oligonucleotide probes using the SeqCap EZ library kit (Roche NimbleGen, Madison, USA) for approximately 65 hrs. After this the exome- enriched libraries were washed and recovered using capture beads. 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: Tyr::CreERT2/;BRafCA/+ genotype Experimental Factor: melanoma disease